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Abstract
Background: The benefit of adjuvant therapy (AT) for gallbladder cancer (GBC) is unclear as evidenced by conflicting
results from nonrandomized studies. Here we aimed to perform a meta-analysis to determine the impact of AT on
overall survival (OS).
Methods: We used data from MEDLINE, EMBASE and the Cochrane Collaboration Library and published between
October 1967 and October 2014. Studies that evaluated AT compared with curative-intent surgery alone for resected
GBC were included. Subgroup analyses of benefit based on node status, margins status, and American Joint Committee
on Cancer (AJCC) staging were prespecified. Data were weighted and pooled using random-effect modeling.
Results: Ten retrospective studies involving 3,191 patients were analyzed. There was a nonsignificant improvement in OS
with AT compared with surgery alone (hazard ratio [HR], 0.76; 95 % confidence interval [CI], 0.56–1.03). A significant
improvement was observed in OS with chemotherapy (CT) compared with surgery alone (HR, 0.42; 95 % CI, 0.22–0.80) by
sensitivity analysis. The greatest benefit for AT was also observed in those with R1 disease (HR, 0.33; 95 % CI, 0.19–0.59),
LN-positive disease (HR, 0.71; 95 % CI, 0.63–0.81), and AJCC staging meeting or exceeding tumor Stage II (HR, 0.45;
95 % CI, 0.26–0.79), but not in those with LN-negative or R0 disease.
Conclusion: Our results strongly support the use of CT as an AT in GBC. Moreover, patients with node positivity,
margin positivity, or non-stage I disease are more likely to benefit from AT.
Background
Gallbladder cancer (GBC) is an uncommon but the most
aggressive biliary tree cancer (BTC). To date, complete sur-
gical resection offers the only chance for cure. Worldwide,
GBC is the sixth most common gastrointestinal cancer
with an annual incidence rate of 2.2 per 100,000 [1, 2]. In
the United States, GBC accounts for approximately 9,760
new cases and 3,370 new deaths per year [3]. However,
only 10 % of patients who present with early-stage GBC
are considered surgical candidates.
A recent study by Valle J et al. showed that longer
overall survival (OS) with gemcitabine in combination
with cisplatin than with gemcitabine alone in patients
with advanced or metastatic BTC [4]. However, estab-
lished adjuvant treatments (AT) for GBC are lacking and
much debate remains about whether AT affects survival
in GBC. Regarding AT for GBC, only one phase III mul-
ticenter prospective randomized controlled trial (RCT)
indicated that patients with gallbladder carcinoma who
undergo R1 but not R0 resections may derive some
benefit from systemic chemotherapy [5]. However, other
trials that had examined the values of AT, including
chemotherapy (CT), radiotherapy (RT), and chemoradio-
therapy (CRT), were limited by their small numbers of
patients in their retrospective and non-randomized study
design.
There are currently no meta-analyses of AT for GBC
on the basis of retrospective data. As such, the aim of
this study was to conduct a meta-analysis to identify
whether AT, i.e., RT, CT, or CRT, could improve OS
compared with surgery alone for the entire group or
subgroups (node status, margins status, American Joint
Committee on Cancer [AJCC] staging, and countries
vary) of GBC on the basis of those retrospective data.
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An electronic search of the MEDLINE, EMBASE and
the Cochrane Collaboration Library were performed
using Internet explorer 10. Searches were limited to
human studies and English-language publications. The
main keywords used for the search were “gallbladder
cancer” and “adjuvant therapy”. The published years
were limited to 1976–2014. A MeSH term search was
performed in MEDLINE. Citation lists of retrieved articles
were manually screened to ensure search sensitivity. We
downloaded the available studies from those databases or
contacted with authors if needed.
Study selection
The relevant clinical trials were manually selected care-
fully based on the following criteria: (1) case–control
design of non-randomized study; (2) patients diagnosed
with GBC according to histopathological or cytological
evidence; (3) patients underwent AT defined as CT, RT,
or both administered after curative-intent surgery, and
patients who underwent curative-intent surgery alone as
a comparator group should be included in those studies;
(4) information collected including hazard ratio (HR) for
OS along with 95 % confidence interval (CI) or relevant
data. When searched references referred to the same
studies, the more recently published and larger studies
were included. We also defined curative-intent resections
as no gross disease remaining (i.e., negative margins [R0]
or microscopic positive margins [R1]), thus excluding
macroscopic involvement (R2) resections [6]. The proced-
ure of inclusion and exclusion criteria of the evaluated
studies was listed in Fig. 1.
Data extraction
Three investigators (Ning Ma,Hui Cheng and Baodong
Qin) searched the publications independently using stan-
dardized data abstraction forms. When the three investiga-
tors discovered different results, an independent expert in
oncology made the final decision. Details such as first
author, year of publication, patient characteristics, insti-
tution, country of study, and patient number must be
included in these publications. T stage, AJCC stage, and
nodal and resection margin statuses were collected. Details
on therapeutic interventions, including surgical procedure,
CT regimen, radiation type and dosage, and treatment
schedule were also collected.
The details of response rate, median/overall survival,
HR for OS (HROS) and their 95 % CI, and adverse events
must be collected as outcomes from these studies. If HR
and 95 % CI were not given, we estimated them as
described below depending on the data provided in the
publication. The estimated HR and its standard error was
obtained from the report results or calculated using two
of the following parameters: the O - E statistic (difference
between numbers of observed and expected events), the
CI for the HR, and the log-rank statistic or its P value. If
these were not available, the total numbers of events,
number of patients at risk in each group, and log rank stat-
istic or its P value were used to allow for an approximation
of the HR estimate [7–9]. In addition, Kaplan-Meier curve
was used to calculate HR and its standard error to verify
those results calculated above. First of all, we divided
Kaplan-Meier plot schematically into time intervals to
obtain the data of survival rates of event-free on research
and control groups. The data of HR, V and O-E then could
be obtained according to the method provided by Tierney
JF et al. [10]. The estimated HR and its standard error
could be obtained according the method mentioned
above, and be verified with the data obtained above. If
this kind of method was used, three independent
persons read the curves to reduce the inaccuracy in the
extracted survival rates.
Statistical analysis
The relative frequencies of survival between AT and
curative-intent surgery alone were expressed as HR and
their 95 % CI. Statistical heterogeneity was tested and a
random effect model was applied at last in calculating
the overall HR. The pooled HR for OS was calculated
then. As for key components of design, rather than quality
scores themselves, may be more important [11], subgroup
Fig. 1 Flow chart showing the progress of trials through the review
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and sensitivity analyses were was designed in our meta-
analysis to identify whether AT could improve OS com-
pared with surgery alone.
Subgroup analyses were conducted that included node-
positive/negative, margin-positive (R1)/negative (R0) dis-
ease, and treatment consisting of CT, RT, or CRT. Few
studies were conducted solely in these populations. Thus,
studies in which ≥50 % of the patients had nodal -posi-
tive/negative, R0/R1 disease on pathology and ≥50 % of
the patients meeting or exceeding tumor stage II were
calculated as the subgroup analysis. All of the analyses
were performed using STATA 11.0. This meta-analysis of




A total of 243 studies met the initial search criteria, and
we identified 11 studies including one RCT [5] and 10
retrospective studies [12–21]. Those 10 retrospective
studies were identified as eligible for inclusion in the
pooled analysis (Fig. 1). These studies incorporated
3,191 patients in which 2,375 were treated with surgery
alone (Lap choly only, Conversion open choly, Radial sec-
ond resection, Primary open choly, or Hemihepatectomy)
and 816 received AT. The details of HR for OS (HROS)
and their 95 % CI were obtained from these studies. The
types of AT,type and duration of chemo, radiation dosing,
and other clinical data of those studies were collected and
listed in Table 1.
Meta-analysis
In calculating the overall HR, statistical heterogeneity
was tested before and the value of p is 0.000. Random
effect model was applied then and as a result, pooled
data showed a nonsignificant improvement in OS with
any AT compared with surgery alone (HR, 0.76; 95 % CI,
0.56–1.03; Fig. 2a) in the overall population.
Subgroup analysis showed a significant improvement
in survival with CT compared with surgery alone (HR,
0.42; 95 % CI, 0.22–0.80) but not statistically significant
compared to CRT (HR, 0.65; 95 % CI, 0.36–1.16) or RT
(HR, 0.64; 95 % CI, 0.26–1.59; Fig. 2b).
Heterogeneity and sensitivity analyses
Margin status
Two studies [19, 21] reporting margin positivity (R1)
(n = 105) according to our prespecified definition
(≥50 %) were analyzed independently [6]. Pooled data
confirmed a significant benefit for AT in margin-
positive patients (HR, 0.33; 95 % CI, 0.19–0.59;
Fig. 3a).
Three studies reporting margin negative (R0) (n = 414)
according to our prespecified definition (≥50 %) were
also analyzed independently [12, 14, 15]. We found that
patients with GBC and R0 resection could not benefit
from AT compared with surgery alone (HROS, 1.29;
95 % CI, 0.91–1.84; Fig. 3a).
Node status
Three studies reporting nodal positive (n = 404) or negative
(n = 1350) according to our prespecified definition (≥50 %)
were analyzed independently [12, 17, 19]. Pooled data
showed a significant benefit for any AT in node-positive
disease (HR, 0.71; 95 % CI, 0.63–0.81; Fig. 3b) but no
statistically significant benefit in node-negative disease
(HR, 0.96; 95 % CI, 0.59–1.56; Fig. 3b).
AJCC staging
As mentioned above, all 11 studies were published
between 1999 and 2012. The 6th AJCC staging was
adopted by most of these studies (AJCC Cancer Staging
Manual, 2002) [22], so clinical disease staging was
adopted according to the AJCC staging system (6th
edition) to avoid stage migration.
AT were less adopted on GBC of Tumor, Node,
Metastasis staging T1 N0M0/T2N0M0. As a result, the
AJCC staging of most of patients in these 11 studies met
or exceeded T2N1M0 or T3N0M0, which is stage II in the
6th AJCC staging system. Among these 11 studies, seven
meeting or exceeding tumor stage II (n = 2,738) according
to our prespecified definition (≥50 %) were analyzed inde-
pendently [13, 15, 17–19, 21]. Pooled data confirmed a
significant benefit for any AT in those patients (HR, 0.45;
95 % CI, 0.26–0.79; Fig. 4a). Subgroup analysis showed a
significant improvement in survival with CT compared
with surgery alone (HR, 0.21; 95 % CI, 0.05–0.88) but not
with RT (HR, 0.48; 95 % CI, 0.17–1.40; Fig. 4a).
To further substantiate our findings, the studies with
100 % of the patients meeting or exceeding tumor stage
II were analyzed independently. Two studies complied
with this (n = 126) [13, 21]. As a result, the pooled data
confirmed a significant benefit for any AT in these patients
(HR, 0.28; 95 % CI, 0.14–0.56; figure not shown).
Results vary among countries
We also analyzed the pooled HR with CI by country.
Our meta-analysis showed a significant improvement in
OS with AT among Asian countries (HR, 0.49; 95 % CI,
0.25–0.96, Fig. 4a, b) but not among non-Asian countries
(HR, 1.11; 95 % CI, 0.71–1.72, Fig. 4a, b).
Evaluation of publication bias
Begg’s funnel plot and Egger’s test were performed to
assess the publication bias of the literature. Evaluation of
publication bias for AT versus surgery alone showed that
both Begg’s and Egger’s test findings were not significant
(p = 0.788 and 0.284) (Fig. 5). The meta-analysis was not
Ma et al. BMC Cancer  (2015) 15:615 Page 3 of 10





No. of patients Adjuvant therapy Outcome Margin positive Margin negative Node positive Node negative Stage≥ II
Treatment Control Therapy Regimen
(details)
Treatment Control Treatment Control Treatment Control Treatment Control Treatment Control
Lee [12] 1994–2011 Korea 135 83 NSR FU/GEM(NR) +
RT(NR)
OS <23 % <37 % >77 % >63 % <27 % <43 % >73 % >57 % NR NR
Subgroup
(CT)
73 83 CT FU/GEM(NR) OS NR NR NR NR NR NR NR NR NR NR
Subgroup
(CRT)
62 83 CRT FU/GEM + RT
(NR)





Japan 11 51 CT GEM + S-1 OS NR NR NR NR NR NR NR NR
Subgroup
(stage II/III)








OS NR NR NR NR NR NR 100 % 100 %

















Week 1 of RT
and repeated
during Week 5)
OS 0 0 100 % 100 % 56 % 13 % 32 % 67 % 80 % 21 %
Liang [15] 1980 to
2005






OS NR NR NR NR NR NR 76 % 92 %




24 99 NSR GEM/FU/GEM
+ Cape +
RT(NR)




























127 277 RT RT(NR) OS NR NR NR NR 100 % 100 % NR NR NR NR
Subgroup
(T3N0)
71 218 RT RT (NR) OS NR NR NR NR NR NR 100 % 100 % NR NR
Subgroup
(T1-2 N0)





India 73 44 CRT CRT (NR) OS NR NR











Itoh [20] 1994 to
2004
Australia 5 13 RT EBRT (total
dose of 45.
2 Gy (range, 45.
0–56. 7) for 2–6
weeks, using a
fraction size of
1. 8–2. 0 Gy)





Japan 47 38 RT IORT + PORT OS 59 % 50 % NR NR NR NR NR NR 100 % 100 %














OS 100 % 100 % NR NR NR NR
NR NR NR NR
Abbreviations: OS overall survival, CT chemotherapy, RT radiation, CRT chemoradiotherapy, NSR non-single regimen (perhaps including CT, RT, and CRT), EBRT external beam radiation therapy, FU fluorouracil,
MMC mitomycin C, NR detail not reported, FU 5-fluorouracil, IORT intraoperative radiotherapy, EBRT external beam radiotherapy, GEM gemcitabine, Cape capecitabine, Cisp cisplatin, Mit mitomycin-C, Dox doxorubicinol,












Fig. 2 Efficacy outcomes for overall population and sensitivity analysis. a. Overall population. b. Sensitivity analysis for overall survival
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Fig. 3 Efficacy outcomes for margin status and node status. a. R0/R1 for OS. b. Node −/+ for OS. c. Stages II and III
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Fig. 4 Efficacy outcomes for difference of country and cumulative meta-analysis over time. a. Different countries. b. Asian/non-Asian countries
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dominated by any individual study, while removing any
study at a time made no difference (data not shown).
These results indicated no evidence of publication bias
in our meta-analysis.
Discussion
GBC is an uncommon cancer but the most aggressive
BTC. Because of the lack of randomized data, there are
no established post-resection AT for GBC [23, 24]. The
aim of our study was to perform a meta-analysis to iden-
tify whether AT could improve OS.
It is well known that meta-analysis is mainly based on
RCT. If there were insufficient RCT, a systemic assess-
ment of non-RCT is needed. According to the Cochrane
systematic review (http://www.cochrane.org/), non-RCT
or retrospective studies may play a complementary role
under these circumstances [11].
The meta-analysis by Horgan et al. recently published
in Journal of Clinical Oncology reported a nonsignificant
improvement in OS with AT compared with surgery
alone for BTC and the GBC subgroup [6, 25]. In that
study, odds ratio (OR) was chosen as the effect label in-
stead of HR. What is more, only four studies including
one RCT and three non-RCT were eligible for inclusion
in that pooled analysis and their results were based on
the study of RCT combined with retrospective and non-
randomized studies. Just as the authors stated, OR is a
less robust measure of survival because it does not con-
sider survival duration prior to death. Contrary to their
study, our meta-analysis was on the basis of retrospective
data and HR instead of OR.
As such, we performed this meta-analysis of our 10 col-
lected studies (involving 3,191 patients in 10 retrospective
studies) to identify whether AT could improve OS com-
pared with surgery alone using HR as the effect label fol-
lowing the methodology described by Parmar et al. [7, 9].
Before this, we excluded the studies that did not provide
case–control design, adjuvant therapy, sufficient detail,
or appropriate comparators. The studies of single case
reports, RCT, and review were also excluded which
mentioned above (Fig. 1). Our pooled analysis demon-
strated a nonsignificant benefit in OS in unselected pa-
tients. Our subgroup analysis showed a significant
improvement in survival with CT (HR, 0.42; 95 % CI,
0.22–0.80) compared with surgery alone but a nonsig-
nificant improvement in survival with RT and CRT.
However, this does not mean that RT and CRT could
not play a positive role since their HR were 0.64 and
0.65, respectively (Fig. 2b).
Similarly with CT in OS, the sensitivity analyses indi-
cated that post-resection AT seems beneficial in subgroups
of high-risk patients, such as those with node and margin
positivity, but not in patients with node negative or R0
disease (Fig. 3a, b). Sensitivity analyses also indicated the
significant benefit of AT, especially CT, in patients with
non-stage I disease (Fig. 3c).
We also conducted our meta-analysis based on na-
tionality. Interestingly, our results showed a significant
improvement in survival with AT in Asian countries
but not in non-Asian countries (Fig. 5a, b). What could
account for the difference? Could differences in race be
a factor? These questions are worthy of future RCT.
The only available RCT showed that the use of adjuvant
RT is associated with improved survival in patients with
LN-positive (P < 0.0001) or stage IIa (T3N0M0) (P = 0.011)
but not in patients with stage I disease [5]. Just as this
study and Horgan [6] showed, our overall analysis also
supports the use of AT for patients with LN-positive, R1,
or AJCC stage > II GBC. It is known that there is a lack of
randomized GBC data, so we performed this meta-analysis
of observational studies without RCT according to the
MOOSE group.
Our study has some limitations. In our Meta analysis,
the quality of the studies included was various and the
observational studies we included had much heterogen-
eity. Selection bias could distort the relationship between
adjuvant therapy and overall survival. Therefore, we used
random-effects modeling, made OS as the only end
point and used sensitivity analyses (RT, CT, CRT, node
status, margins status, AJCC stage, and multiple country
analysis) to address this. As mentioned above, we calcu-
lated HR and 95 % CI using two of the following parame-
ters: the O - E statistic, the CI for the HR, and the log-rank
statistic or its P value. As we know, this kind of estimated
value not the true value. To ensure the accuracy of the
results, three investigators (Ning Ma,Hui Cheng and
Baodong Qin) calculated HR and 95 % CI independently.
Furthermore, Kaplan-Meier curve was also used if possible
to calculate HR and 95 % CI to verify these results.
In addition,on the one hand, as most of the included
studies were small sample case–control studies, the
possibility of a type II error exists. On the other hand,
the results of the non-RCT may be overstated. Begg’s
Fig. 5 Begg’s funnel plot
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funnel plot and Egger’s test were performed to assess the
publication bias of the literature. As a result, these
results indicated no evidence of publication bias in our
meta-analysis.
Conclusion
Our analysis provides reasonable support for the use of
CT as an AT in patients with GBC. Moreover, patients
with node positivity, margin positivity, or non-stage I
disease are more likely to benefit from AT. We believe
that the results of our meta-analysis will contribute to the
use of CT as an AT in patients with GBC, especially those
with the high risk factors described above. However our
meta-analysis is based on the observational studies and
not randomized controlled trial (RCT). Further research
especially RCT is needed to better characterize the benefit
of adjuvant therapy for gallbladder cancer.
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